Skip to main content
Journal cover image

Why develop antidotes and reversal agents for non-vitamin K oral anticoagulants?

Publication ,  Journal Article
Washam, JB; Piccini, JP
Published in: J Thromb Thrombolysis
February 2016

Over the past several years, non-vitamin K oral anticoagulants (NOACs) have been introduced into clinical practice for the treatment of venous thromboembolism and prevention of stroke in patients with nonvalvular atrial fibrillation. Clinical trials have shown these agents to have similar or less risk of major bleeding as compared to warfarin therapy. Moreover, when patients do experience a major bleeding event administration of advanced factor products is rare, and post-bleed outcomes are similar in those receiving a NOAC compared to those receiving warfarin. However, there are situations where urgent reversal of NOAC anticoagulation would be desirable. The following review focuses on the outcomes and management strategies for patients experiencing a major bleed with warfarin or NOAC agents and describes the rationale for the development of therapies capable of targeted NOAC-reversal.

Duke Scholars

Published In

J Thromb Thrombolysis

DOI

EISSN

1573-742X

Publication Date

February 2016

Volume

41

Issue

2

Start / End Page

279 / 284

Location

Netherlands

Related Subject Headings

  • Vitamin K
  • Venous Thromboembolism
  • Stroke
  • Humans
  • Hemorrhage
  • Cardiovascular System & Hematology
  • Antidotes
  • Anticoagulants
  • Animals
  • Administration, Oral
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Washam, J. B., & Piccini, J. P. (2016). Why develop antidotes and reversal agents for non-vitamin K oral anticoagulants? J Thromb Thrombolysis, 41(2), 279–284. https://doi.org/10.1007/s11239-015-1296-1
Washam, Jeffrey B., and Jonathan P. Piccini. “Why develop antidotes and reversal agents for non-vitamin K oral anticoagulants?J Thromb Thrombolysis 41, no. 2 (February 2016): 279–84. https://doi.org/10.1007/s11239-015-1296-1.
Washam JB, Piccini JP. Why develop antidotes and reversal agents for non-vitamin K oral anticoagulants? J Thromb Thrombolysis. 2016 Feb;41(2):279–84.
Washam, Jeffrey B., and Jonathan P. Piccini. “Why develop antidotes and reversal agents for non-vitamin K oral anticoagulants?J Thromb Thrombolysis, vol. 41, no. 2, Feb. 2016, pp. 279–84. Pubmed, doi:10.1007/s11239-015-1296-1.
Washam JB, Piccini JP. Why develop antidotes and reversal agents for non-vitamin K oral anticoagulants? J Thromb Thrombolysis. 2016 Feb;41(2):279–284.
Journal cover image

Published In

J Thromb Thrombolysis

DOI

EISSN

1573-742X

Publication Date

February 2016

Volume

41

Issue

2

Start / End Page

279 / 284

Location

Netherlands

Related Subject Headings

  • Vitamin K
  • Venous Thromboembolism
  • Stroke
  • Humans
  • Hemorrhage
  • Cardiovascular System & Hematology
  • Antidotes
  • Anticoagulants
  • Animals
  • Administration, Oral